help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 8, 958, September 2006; doi:10.1634/theoncologist.11-8-958
© 2006 AlphaMed Press

This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

Erratum

Combined Modality Therapy For Stage III Non-Small Cell Lung Cancer

THOMAS E. STINCHCOMBE, DANIEL FRIED, DAVID E. MORRIS, MARK A. SOCINSKI

The Oncologist 2006;11:809–823

On page 813, there were errors in the text. Here we print the correct text.

CONSOLIDATION THERAPY

In a recent phase II trial by SWOG (S9504), patients with stage IIIB disease were treated with systemic-dose cisplatin plus etoposide and concurrent TRT (total dose, 61 Gy) and additional consolidation chemotherapy with docetaxel (Taxotere®; Aventis Pharmaceuticals Inc, Bridgewater, NJ) at a dose of 75 mg/m2 for the first cycle with dose escalation to 100 mg/m2 for the second and third cycles in the absence of significant toxicity [19]. The survival data, based on 83 patients, revealed an impressive median survival time of 26 months, and the 1-, 2-, and 3-year survival rates were 76%, 54%, and 37%, respectively. This compared favorably to the previous SWOG trial (S9019) which had a median survival of 15 months, and the 1-, 2-, 3 -year survival rates were 58%, 34%, and 17%, respectively. Sixty-five of the patients were able to proceed to the consolidation chemotherapy, and 49 patients were able to receive all three cycles of the docetaxel. The main toxicity seen in the consolidation chemotherapy portion of the treatment was myelosuppression, with a grade 4 neutropenia rate of 57% and a rate of febrile neutropenia of 9%. Three patients died of pulmonary complications, which consisted of probable radiation pneumonitis in two patients and aspiration pneumonia in one patient.





This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml